Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

DNMT3A with Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks

Kartika Venugopal, MS, Daniil E Shabashvili, PhD, Jianping Li, MD, Luisa M Posada, Richard Lynn Bennett, PhD, Yang Feng, MS, Daphne Dupere Richer, PhD, Alberto Riva, PhD, Santhi Pondugula, PhD, Jonathan E. Bird, PhD, Jonathan D. Licht, MD, Olga A Guryanova, MD PhD

Blood (2019) 134 (Supplement_1): 535.

https://doi.org/10.1182/blood-2019-128213

Published: 2019

Journal Articles

Cells with DNMT3A Mutations Are More Sensitive to Cytarabine-Induced DNA Damage

Kartika Venugopal, MS, Jianping Li, MD, Daniil E Shabashvili, PhD, Luisa M Posada, Yang Feng, MS, Daphne Dupere-Richer, PhD, Aditya Bele, PhD, Jonathan D. Licht, MD, Olga A Guryanova, MD PhD

Blood (2018) 132 (Supplement 1): 2643.

https://doi.org/10.1182/blood-2018-99-118708

Published: 2018

Journal Articles

Prmt5 Negatively Regulates Erythropoiesis By Multiple Mechanisms, Including Controlling DNA Methyltransferase 3A Protein Levels

Pierre-Jacques Hamard, PhD, Luisa Luciani, PhD, Fan Liu, PhD, Guoyan Cheng, PhD, Megan A. Hatlen, PhD, Olga A Guryanova, MD, PhD, Xinyang Zhao, PhD, Ross L. Levine, MD, Stephen D. Nimer, MD

Blood (2015) 126 (23): 1181.

https://doi.org/10.1182/blood.V126.23.1181.1181

Published: 2015

Journal Articles

Characterizing Transcriptional and Epigenetic Signatures Induced By FLT3-ITD Activation

Barbara Spitzer, MD, Olga A Guryanova, MD PhD, Omar Abdel-Wahab, MD, Nicole Kucine, MD, Mazhar Adli, PhD, Jason N. Berman, MD, Soheil Meshinchi, MD PhD, Bradley Bernstein, MD PhD, Raphael Pelossof, PhD, Christina Leslie, PhD, Ross L. Levine, MD

Blood (2014) 124 (21): 2186.

https://doi.org/10.1182/blood.V124.21.2186.2186

Published: 2014

Journal Articles

Conditional Loss of Dnmt3a Results in Myeloproliferation and Liver-Specific Myeloid Expansion

Olga A Guryanova, MD PhD, Yen Lieu, PhD, Kaitlyn R Shank, B.S., Sharon Rivera, PhD, Francine E Garrett-Bakelman, MD PhD, Jacob Glass, MD PhD, Matthew D Keller, B.S., Suveg Pandey, B.S., Daniel Tovbin, Abby R Weinstein, Julie Teruya-Feldstein, MD, Omar Abdel-Wahab, MD, Christopher E Mason, PhD, Ari M Melnick, MD, Siddhartha Mukherjee, MD PhD, Ross L. Levine, MD

Blood (2014) 124 (21): 364.

https://doi.org/10.1182/blood.V124.21.364.364

Published: 2014

Journal Articles

Type II Inhibition of JAK2 with NVP-CHZ868 Reverses Type I JAK Inhibitor Persistence and Demonstrates Increased Efficacy in MPN Models

Sara C Meyer, MD PhD, Matthew D Keller, BS, Priya Koppikar, PhD, Olga A Guryanova, MD PhD, Maria Kleppe, PhD, Anna Sophia McKenney, MPH, William R Sellers, MD, Francesco Hofmann, PhD, Fabienne Baffert, Christoph Gaul, PhD, Thomas Radimerski, PhD, Ross L Levine, MD

Blood (2014) 124 (21): 160.

https://doi.org/10.1182/blood.V124.21.160.160

Published: 2014

NARROW

DNMT3A with Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks

Cells with DNMT3A Mutations Are More Sensitive to Cytarabine-Induced DNA Damage

Prmt5 Negatively Regulates Erythropoiesis By Multiple Mechanisms, Including Controlling DNA Methyltransferase 3A Protein Levels

Characterizing Transcriptional and Epigenetic Signatures Induced By FLT3-ITD Activation

Conditional Loss of Dnmt3a Results in Myeloproliferation and Liver-Specific Myeloid Expansion

Type II Inhibition of JAK2 with NVP-CHZ868 Reverses Type I JAK Inhibitor Persistence and Demonstrates Increased Efficacy in MPN Models

Email alerts

ASH Publications

American Society of Hematology

DNMT3A with Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks

Cells with DNMT3A Mutations Are More Sensitive to Cytarabine-Induced DNA Damage

Prmt5 Negatively Regulates Erythropoiesis By Multiple Mechanisms, Including Controlling DNA Methyltransferase 3A Protein Levels

Characterizing Transcriptional and Epigenetic Signatures Induced By FLT3-ITD Activation

Conditional Loss of Dnmt3a Results in Myeloproliferation and Liver-Specific Myeloid Expansion

Type II Inhibition of JAK2 with NVP-CHZ868 Reverses Type I JAK Inhibitor Persistence and Demonstrates Increased Efficacy in MPN Models

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only